Yang and coworkers (2020) reported that brusatol, a modern Nrf2 inhibitor, showed anti-tumor properties, which were shown as decreased cancer cell growth by suppressing the Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling in HER2-positive cancer cells (SK-OV-3 and BT-474 cells) [74]. The gene discussed is MAPK3; the disease is cancer.